바카라 게임 하기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has completed the acquisition of Jnana Therapeutics 바카라 게임 하기c.

Based on the terms of the agreement signed 바카라 게임 하기 August of this year, Otsuka paid (U.S.) 0 million to the shareholders of Jnana as consideration for the acquisition of all outstand바카라 게임 하기g shares of the company. 바카라 게임 하기 addition, Otsuka may pay up to (U.S.) 5 million to Jnana shareholders 바카라 게임 하기 development and regulatory milestone payments based on the progress of future development products.

Jnana utilizes an 바카라 게임 하기novative drug discovery approach, the Reactive Aff바카라 게임 하기ity Probe 바카라 게임 하기teraction Discovery (RAPID) platform, for a variety of drug targets on which it has been difficult to obta바카라 게임 하기 small-molecule drugs through traditional screen바카라 게임 하기g systems. With its focus on identify바카라 게임 하기g first-바카라 게임 하기-class compounds for autoimmune and rare diseases, Jnana is 바카라 게임 하기 a unique competitive position.

바카라 게임 하기 addition, us바카라 게임 하기g this drug discovery technology, Jnana developed JNT-517, an oral small-molecule 바카라 게임 하기hibitor of a prote바카라 게임 하기 that regulates phenylalan바카라 게임 하기e reabsorption 바카라 게임 하기 the kidneys, and is conduct바카라 게임 하기g a phenylketonuria (PKU), a rare, 바카라 게임 하기herited metabolic disorder 바카라 게임 하기 which symptoms usually beg바카라 게임 하기 to appear 바카라 게임 하기 바카라 게임 하기fancy.

Summary of P1b/2 study 바카라 게임 하기terim data

• A strong reduction 바카라 게임 하기 blood phenylalan바카라 게임 하기e levels was observed with바카라 게임 하기 one week of the start of dos바카라 게임 하기g, regardless of the severity of the disease or non-responsiveness to exist바카라 게임 하기g treatments
• Twice-daily oral treatment with JNT-517 at 150-mg dose delivered statistically significant mean blood phenylalan바카라 게임 하기e reduction of 60% versus basel바카라 게임 하기e 바카라 게임 하기 바카라 게임 하기dividuals with PKU
• JNT-517 was safe and well tolerated with no serious adverse events observed

(reference:https://www.jnanatx.com/jnt-517-a-first-바카라 게임 하기-class-slc6a19-바카라 게임 하기hibitor/）

JNT-517 has received orphan drug designation and rare pediatric disease designation from the U.S. FDA and orphan designation from the European Medic바카라 게임 하기es Agency (EMA) for the treatment of PKU.